Compounds of formula (I)
Z-Ar
1
—Ar
2
(I)
wherein Z is a diazabicyclic amine, Ar
1
is a 5- or 6-membered aromatic ring, and Ar
2
is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
Compounds of formula (I)
wherein A is N or N
+
—O
−
; n is 0, 1, or 2; Y is O, S, —NH—, and —N-alkyl-; Ar
1
is both 6-membered aromatic rings; Ar
2
is 5- or 6-membered aromatic rings with a —NR
8
R
9
group, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
Compounds of formula (I)
wherein n is 0, 1, or 2; A is N or N
+
—O
−
; X is O, S, —NH—, and —N-alkyl-; Ar
1
is a 6-membered aromatic ring; and Ar
2
is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.
A series of 3,6-diaryl-[1,2,4]triazolo[4,3-b]pyridazines were designed as a class of vinylogous CA-4 analogues. The easily isomerized (Z,E)-butadiene linker of vinylogous CA-4 was replaced by a rigid [1,2,4]triazolo[4,3-b]pyridazine scaffold. Twenty-one target compounds were synthesized and exhibited moderate to potent antiproliferative activity. The compound 4q with a 3-amino-4-methoxyphenyl moiety
一系列3,6-二芳基-[1,2,4]三唑并[4,3- b ]哒嗪被设计为一类乙烯基CA-4类似物。乙烯基CA-4的易于异构化的(Z,E)-丁二烯连接基被刚性的[1,2,4]三唑并[4,3- b ]哒嗪支架取代。合成了二十一种目标化合物,它们具有中等至有效的抗增殖活性。与CA-4(IC 50 = 0.009–0.012μM)相比,具有3-氨基-4-甲氧基苯基部分作为B环的化合物4q显示出对SGC-7901,A549和HT-的高活性抗增殖活性具有IC 50的1080个细胞系值分别为0.014、0.008和0.012μM。微管蛋白聚合实验表明,4q有效抑制微管蛋白聚合,免疫染色测定表明4q显着破坏微管蛋白微管动力学。此外,细胞周期研究表明,化合物4q在A549细胞的G2 / M期显着阻止了细胞周期进程。分子模型研究表明4q可以与微管上的秋水仙碱结合位点结合。